Synthetic Biologics, Inc.

9:30 AM - 9:45 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
Synthetic Biologics, Inc. is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead late-stage candidates are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics to prevent microbiome damage, C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company’s preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases.
Ticker:
SYN
Exchange:
NYSE American
Company Type:
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
SYN-010
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3